Therefore, Toll-like receptor 2 and Toll-like receptor 4 are potential targets to develop new therapies to alter the course of disease in people at high risk of Parkinson’s disease and improve gut disorders in patients in the prodromal phase or with established disease. Here, TLR2 is linked to Parkinson disease.